Pune, India, Jan. 25, 2021 (GLOBE NEWSWIRE) -- The global immunomodulators market is set to gain momentum from the increasing research activities to introduce unique approaches to treat cancer effectively. This information is published by Fortune Business Insights™ in a new study, titled, “Immunomodulators Market Size, Share & COVID-19 Impact Analysis, By Product Type (Immunosuppressant, Immunostimulants), By Application (Oncology, Respiratory, Multiple Sclerosis, and Others), and Regional Forecast, 2020-2027.” The study further mentions that the market size was USD 161.57 billion in 2019. It is projected to grow from USD 186.12 billion in 2020 to USD 285.01 billion in 2027 at a CAGR of 6.3% during the forecast period.
Rising Cases of Rheumatoid Arthritis to Accelerate Growth
The higher prevalence of multiple sclerosis is considered to be the second major cause of death, followed by cardiovascular disorders. The rising number of ongoing clinical trials to develop immunotherapeutic agents, namely, laquinimod, ozanimod, and ponesimod would propel the immunomodulators market in the upcoming years. Apart from that, the rising need to treat autoimmune disorders, such as rheumatoid arthritis is anticipated to spur demand. However, immunomodulators can cause severe infections including HIB, TB, fungal infections, hepatitis B, and hepatitis C viruses. These factors may hinder the demand for such drugs.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/immunomodulators-market-104692
Immunosuppressant Segment Held Highest Share Fueled by Rising Availability of Drugs
Based on the product type, the immunosuppressant segment held the majority of the immunomodulators market share in 2019. This growth is attributable to the usage of these drugs for treating autoimmune disorders, such as lupus and alopecia areata. Also, the presence of a wide range of these drugs capable of effectively treating the above-mentioned diseases would boost growth of the segment.
Investment in Quality Control to Favor Growth amid COVID-19 Pandemic
The COVID-19 pandemic is set to affect the market positively in the near future backed by the increasing sales of these products. Besides, numerous pharmaceutical companies are aiming to maintain the balance between demand and supply to keep their sales intact. They are also trying to invest more in quality control, refine their R&D activities, and enhance the supply chain management. We are offering in-depth analysis of the market to help you invest in the right zones.
To get to know more about the short-term and long-term impact of COVID-19 on this market, please visit: https://www.fortunebusinessinsights.com/immunomodulators-market-104692
Increasing Prevalence of Chronic Diseases to Drive Growth in North America
Geographically, in 2019, North America procured USD 61.91 billion in terms of revenue. The region is expected to retain its dominant position throughout the forthcoming years on account of the surging incidence of chronic diseases in the U.S. Europe, on the other hand, is set to remain in the second position backed by the increasing sales of immunosuppressant products in the region. In Asia Pacific, would show the highest CAGR stoked by the rising number of ongoing studies associated with immunomodulators. Also, the increasing geriatric population would intensify demand in the region.
Key Players Focus on Introducing State-of-the-art Drugs to Gain a Competitive Edge
The global market for immunomodulators contains a large number of big, small, and medium companies. Most of them are striving persistently to gain a competitive edge in the market. To do so, they are coming up with novel immunomodulators to treat various chronic diseases. Below are the two latest industry developments:
- October 2020: Cytocom, Inc. and Cleveland BioLabs, Inc. signed a merger agreement to blend their businesses in an individual transaction. This merger will transform the growth opportunity for Cleveland and Cytocom shareholders. It will also strengthen their positions and accelerate their potential to treat serious medical conditions with immune-modulating agents.
- January 2020: Bristol Myers Squibb introduced its latest drug named Zeposia to treat multiple sclerosis. It can not only address less recognized cognitive issues but also the physical aspects of multiple sclerosis.
Quick Buy - Immunomodulators Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/104692
A list of all the reputed immunomodulators providers operating in the global market:
- F. Hoffmann-La Roche Ltd (Basel, Switzerland)
- Novartis AG (Basel, Switzerland)
- Biogen (Massachusetts, U.S.)
- Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel)
- Amgen, Inc (California, U.S.)
- Bristol-Myers & Squibb Company (New York, U.S)
- Merck Sharp & Dohme Corp. (New jersey, U.S)
- Eli Lilly and Company (Indiana, U.S)
- Other Players
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/immunomodulators-market-104692
Table of Contents:
- Introduction
- Market Scope
- Market Segmentation
- Market Methodology
- Definitions and Assumptions
- Executive Summary
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Key Insights
- Prevalence of Key Disease Conditions –Key Regions/Country
- New Product Launch
- Pipeline Analysis
- Impact of COVID-19 on the Immunomodulators Market
- Key Industry Developments - Mergers, Acquisitions, and Partnerships
- Global Immunomodulators Market Analysis, Insights and Forecast, 2016-2027
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Product Type
- Immunosuppressants
- Immunostimulants
- Market Analysis, Insights and Forecast – By Application
- Respiratory
- Oncology
- Multiple Sclerosis
- Others
- Market Analysis, Insights and Forecast – By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/immunomodulators-market-104692
SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:
- Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companies
- Details in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc.
- Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facility
- Number of procedures and average price of procedures
- Replacement rate and pricing of capital equipment
- Market dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunities
- Market & technological trends, new product developments, product pipeline.
Have a Look at Related Reports:
Aesthetic Implants Market Share & Industry Analysis, By Product (Breast Implants, Dental Implants, Facial Implants & Others), By Gender (Female, Male), By End-user (Hospitals, Specialty Clinics), and Regional Forecast, 2019-2026
Veterinary/Animal Vaccines Market Share & Industry Analysis, By Product (Inactivated, Live Attenuated, Recombinant, Others), By Animal (Companion, Livestock), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Veterinary Hospitals, Veterinary Clinics, Pharmacies & Drug Stores, Others) and Regional Forecast, 2019-2026
Aesthetic/Cosmetic Lasers Market Share & Industry Analysis, By Application (Hair Removal, Pigmentation & Tattoo Removal, Body Shaping & Tightening, Skin rejuvenation, Acne Reduction, and Others), By End User (Hospitals and Specialty Clinics) and Regional Forecast, 2019-2026
Hearing Aids Market Share & Industry Analysis, By Product (Hearing Devices, Hearing Implants), By Patient Type (Adult, Pediatric), By Distribution Channel (OTC (Over the Counter), Medical Channel/ Hospital Pharmacies, Private Practice/ Retail Pharmacies) and Regional Forecast, 2019-2026
Microfluidic Devices Market Share & Industry Analysis, By Device Type (Chips, Sensors, and Others), By Material (Glass, Silicon, Polymer and Others), By Applications (Pharmaceutical & Life Science Research, Diagnosis & Treatment, and Others), By End-user (Diagnostic Centers, Research Institutes, Pharmaceutical and Biotechnology Companies, Healthcare Facilities and Others) and Regional Forecast, 2019-2026
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs
Press Release: https://www.fortunebusinessinsights.com/press-release/global-immunomodulators-market-10475